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Sequestering HMGB1 via DNA-Conjugated Beads
Ameliorates Murine Colitis
Zhongliang Ju1., Sangeeta S. Chavan1., Daniel J. Antoine2, Meghan Dancho1, Teá Tsaava1, Jianhua Li1,
Ben Lu1, Yaakov A. Levine3, Andrew Stiegler4, Yehuda Tamari4, Yousef Al-Abed5, Jesse Roth1,
Kevin J. Tracey1, Huan Yang1*
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Abstract
Inflammatory bowel disease (IBD) is chronic inflammation of the gastrointestinal tract that affects millions of people
worldwide. Although the etiology of IBD is not clear, it is known that products from stressed cells and enteric microbes
promote intestinal inflammation. High mobility group box 1 (HMGB1), originally identified as a nuclear DNA binding protein,
is a cytokine-like protein mediator implicated in infection, sterile injury, autoimmune disease, and IBD. Elevated levels of
HMGB1 have been detected in inflamed human intestinal tissues and in feces of IBD patients and mouse models of colitis.
Neutralizing HMGB1 activity by administration of anti-HMGB1 antibodies or HMGB1-specific antagonist improves clinical
outcomes in animal models of colitis. Since HMGB1 binds to DNA with high affinity, here we developed a novel strategy to
sequester HMGB1 using DNA immobilized on sepharose beads. Screening of DNA-bead constructs revealed that B2 beads,
one linear form of DNA conjugated beads, bind HMGB1 with high affinity, capture HMGB1 ex vivo from endotoxinstimulated RAW 264.7 cell supernatant and from feces of mice with colitis. Oral administration of B2 DNA beads significantly
improved body weight, reduced colon injury, and suppressed colonic and circulating cytokine levels in mice with
spontaneous colitis (IL-10 knockout) and with dextran sulfate sodium-induced colitis. Thus, DNA beads reduce inflammation
by sequestering HMGB1 and may have therapeutic potential for the treatment of IBD.
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diseases [10–12]. HMGB1 has recently been implicated in the
pathogenesis of IBD. In IBD patients and mice with colitis,
HMGB1 is secreted by inflamed intestinal tissues and present at
high levels in the feces [13,14]. The large quantities of HMGB1 in
the gastrointestinal tract mediate inflammation and gastrointestinal barrier failure [15,16]. Neutralizing HMGB1 activity by
administration of anti-HMGB1 antibodies or ethyl pyruvate
attenuates colon injury, reduces weight loss and improves colon
scores in animal models of colitis [13,14,17,18]. Together these
findings suggest that HMGB1 could be an important therapeutic
target in IBD.
Recent extensive studies have demonstrated that redox state of
HMB1 determines both intracellular and extracellular functions of
HMGB1. Importantly, HMGB1 contains three cysteines (C23,
C45 and C106), each of which is susceptible to redox modification
[19].The redox state of these cysteine residues determines the
biological activity of extracellular HMGB1 [19–21]. Cytokinestimulating HMGB1 has C23 and C45 in a disulfide linkage and

Introduction
Inflammatory Bowel Disease (IBD), which includes ulcerative
colitis and Crohn’s disease, is one of the five most prevalent
gastrointestinal diseases, with an annual cost of more than $1.7
billion in the United States [1–3]. The etiology of IBD remains
unclear, but it is associated with a considerable reduction in
quality of life and significant morbidity [4–7]. Despite significant
progress in the management of the disease, curative treatment
options are not yet available. Current therapeutics targeting
excessive cytokine production or using immune-suppressive
regimens have had limited success [3,4,8].
High mobility group box 1 (HMGB1) is a ubiquitous nuclear
protein involved in nucleosome stabilization, gene transcription
and neurite outgrowth [9]. During infection or injury, activated
immune cells and damaged cells release HMGB1 into the
extracellular space, where HMGB1 functions as a pro-inflammatory mediator and contributes to the pathogenesis of inflammatory
PLOS ONE | www.plosone.org
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C106 in its reduced form with a thiol side chain and has been
recently re-named as disulfide HMGB1. When all cysteine
residues are reduced, HMGB1 acts as a chemotactic mediator,
this molecular form has been recently named fully reduced
HMGB1 [22]. When all cysteine residues are terminally oxidized
to the sulphonate, HMGB1 has no cytokine-stimulating or
chemotactic activity (sulfonyl HMGB1). Other post-translational
modifications such as acetylation and phosphorylation have been
implicated in the regulation of HMGB1 release. HMGB1 contains
two nuclear localization sequences (NLS), and lysine residues in
NLS regions are susceptible to acetylation modification. It has
been shown that hyperacetylation of HMGB1 at the NLS results
in nuclear exclusion and subsequent HMGB1 release [23–25].
HMGB1 exerts strong binding to DNA including linear, bends,
bulges and four-way junctions [9,26–28]. The DNA-binding
property of HMGB1 has been utilized to neutralize HMGB1
cytokine activity, reduce immune responses and ameliorate the
severity of diseases in animal models of inflammation associated
with elevated levels of HMGB1 [29,30]. Here we developed a
novel strategy to sequester HMGB1 using DNA immobilized on
sepharose beads (45–165 mm, average size 90 mm). These DNA
beads bind HMGB1 with high affinity, capture HMGB1 ex vivo
from activated RAW 264.7 cell supernatants and from feces of
colitis mice. When administered orally, these DNA beads improves
body weight, reduces colon injury and suppresses colonic and
circulating cytokine levels in mice with spontaneous colitis (IL-10
knockout mice) or with dextran sulfate sodium-induced colitis.

Generation of oligos
We selected four different DNA constructs that were reported to
have high binding affinity to HMGB1, including two nonimmunogenic linear DNA (S1 and S2 [30], Kd to
HMGB1 = 5 nM for both), 4-way junction DNA (S3, Kd to
HMGB1 = 1 nM, [28]) and a kinked duplex DNA (S4, Kd to
HMGB1 = 22 nM, [29]) (Table 1). S1 refers to 12–20.1; S2 refers
to 12–20.2; S3 refers to 12-4WJ.1; S4 refers to 12-DP.1.
All oligonucleotides (sequences 1–8, Table 1) were made by
Genemed Synthesis, Inc. (San Antonio, TX). A C6 amino group
linker [NH2(CH2)6O-P(O)2] was conjugated to the 59 of the
following oligos: sequences 1, 2, 3 and 7. To prevent DNase
degradation, oligos were synthesized with phosphorothioate for
two linear forms of DNA S1 and S2 and with phosphodiester
backbone for DNA forms of S4 and S3 throughout the sequences.
The oligos were selected and synthesized according to previous
publications [28–30].

Preparation of DNA beads
Conjugation of DNA to CNBr sepharose beads was carried out
as described by Chockalingam et al [31]. The coupling efficiency
of the samples was calculated by measuring the pre- and postcoupling OD260 and the percentage of the DNA immobilized to
sepharose beads after the coupling reaction. Control beads were
prepared using the same procedure but without adding DNA. The
beads coated with S1, S2, S3 and S4 were referred as B1, B2, B3
and B4 beads respectively. Approximately 8 nmol of S1 and S2
DNA (48 mg), 4 nmol of S3 and S4 DNA (180 mg) were bound to
each ml of drained beads.

Materials and Methods
Materials

Binding ratio of HMGB1 to DNA beads

CNBr-activated sepharose 4 fast flow resin and CM5 dextran
sensor chip were from GE healthcare (Piscataway, NJ). Lipopolysaccharide (LPS, E. Coli. 0111:B4), Recombinant human histone
H3, triton X-100 and protease inhibitors were purchased from
Sigma (St. Louis, MO). Dextran sulfate sodium (MW = 36,000–
50,000 Da) was purchased from MP Biomedicals (Solon, OH).
RAW 264.7 (TIB-71), HELA (CCL-2) and Caco-2 (HTB-37) cells
were obtained from American type culture collection (Rockville,
MD). Human TNF and anti-human TNF antibody were
purchased from R & D system Inc. (Minneapolis, MN). The
lactate dehydrogenase (LDH) cytotoxicity kit was from Takara
Inc., (Otsu, Shiga, Japan). HMGB1 ELISA kit was from IBL
international (Hamberg, Germany). QIAzol lysis reagent was from
Qiagen (Valencia, CA). One step RT-PCR kit was obtained from
Eurogentec (Fremont, CA). Poly I:C was from InvivoGen (San
Diego, CA). Light Cycler 480 instrument was purchased from
Roche Diagnostics (Munich, Germany). RNase free DNase I and
anti-histone H3 antibody were purchased from Thermo Scientific
(Rockford, IL). Superscript III First-strand Synthesis System for
cDNA synthesis was purchased from Invitrogen (Grand Island,
NY). Microcon centrifugal filters were from Millipore (Billerica,
MA).

Each of the three DNA-beads showed maximum binding at
2 mg HMGB1 which corresponds to 76 pmols of HMGB1. The
concentration of DNA in beads is approximately 8 mM for B1 and
B2, and 4 mM for B3. Given that 76 pmoles of HMGB1 bound
5 ml of DNA beads, it was calculated that the binding ratio of
HMGB1 to B1 and B2 beads is 2:1 (76 pmoles HMGB1 per
40 pmoles of DNA = 2) and for B3 is 4:1 (76 pmoles HMGB1 per
20 pmoles of DNA = 4).

Binding of HMGB1 and DNA beads
The binding ability and affinity of the DNA beads to HMGB1
was tested using a depletion approach. A fixed amount of drained
DNA beads B1, B2, B3 and B4 (5 ml) were incubated with
HMGB1 at 0, 0.01, 0.1, 0.2, 0.5, 1, 2 and 3 mg in a total volume of
50 ml at room temperature for two hours with rotation.
Alternatively fixed amount of HMGB1 (2 mg) was incubated with
increasing amounts of DNA beads (0, 0.2, 1.5, 5, and 15 ml
drained DNA beads) in a total volume to 100 ml for 2 hours at
room temperature with rotation. The bound and free HMGB1
was analyzed by western blot [32]. To determine binding kinetics,
DNA beads (20 ml) were incubated with 500 ng of HMGB1 in
50 ml PBS for 0, 15, 30, 60, 120, 240 or 960 minutes at room
temperature and the amount of HMGB1 bound to the beads was
measured by western blot.

Cell culture
Cells (RAW 264.7, Hela and Caco 2) were cultured in DMEM
supplemented with 10% or 20% (for Caco2 cells) of fetal bovine
serum, 100 U/ml penicillin and 100 mg/ml streptomycin. Cells
were used at 90% confluence and treatment was carried out in
serum-free Opti-MEM I medium (Life Technologies, Carlsbad,
CA). Human primary monocytes were purified by density gradient
centrifugation through Ficoll from blood donated by healthy
volunteers to the Long Island Blood Bank (New York Blood
Center, Melville, NY) as previously described [11].
PLOS ONE | www.plosone.org

FAM-labeled B2 DNA-beads
Carboxyl terminal FAM-labeled S2 conjugated to sepharose
beads were made by Genemed Synthesis Inc (San Antonio, TX).
Fecal extract from colitis mice (300 ml) was incubated with FAMlabeled B2 beads (50 ml) at 37uC. After 2 hours incubation, beads
were washed five times with PBS and re-suspended as 50% slurry.
The fluorescence intensity in both supernatants and beads (before
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Table 1. Design of DNA oligos.

DNA

Oligos

Sequence 59 to 39

Affinity (Kd)

S1

1

AmC6AGCATGAGGTTCCTGATGCT

5 nM

S2

2

AmC6TGGATGAGCTTCCTGATGTC

5 nM

S3

3

AmC6CCCTATAACCCCTGCATTGAATTCCAGTCTGATAA

1 nM [28]

4

GTAGTCGTGATAGGTGCAGGGGTTATAGGG

5

AACAGTAGCTCTTATTCGAGCTCGCGCCCTATCACGACTA

6

TTTATCAGACTGGAATTCAAGCGCGAGCTCGAATAAGAGCTACTGT

S4

7

AmC6CTTGCATTGAAATTTCTTTCC

8

GAACGTAACAAAGAAAGG

22 nM [29]

Four DNA molecules (S1–S4) were selected for this study [28–30]. An amino linker (Am) was added to 59 end of sequences 1, 2, 3 and 7. Biacore T200 was used for
analysis of binding between HMGB1 (coated on the chip) and DNA S1 and S2 (0–10 mM, Methods). HMGB1 binds in a similar manner to both S1 and S2, in an HMGB1
concentration-dependent manner and with high affinity (Kd = 5 nM). Data are representative of two repeats.
doi:10.1371/journal.pone.0103992.t001

murine macrophage-like RAW 264.7 cells were incubated with
LPS (2 ng/ml), poly I:C (1 mM), S1 or S2 (1 mM), or B1 and B2
beads (100 ml) for 24 hours at 37uC. Total RNA was extracted
using QIAzol Lysis Reagent, and treated with DNase I to remove
any contaminated genomic DNA. cDNA was synthesized by using
a Superscript III First-strand Synthesis kit. The levels of IFN-b
mRNA were analyzed by quantitative PCR using a Roche Light
Cycler 480. Primers sequences used in IFN-b PCR amplification
were as follows: forward 59GCATCACCTGCTATGGGATT39
and reverse 59TACCCCAGGTTCTGGCTTTA39. The PCR
amplification was performed by denaturing the DNA at 95uC for
10 min, followed by 45 cycles of denaturing at 95uC for
10 seconds, annealing at 60uC for 30 seconds, and an extension
at 72uC for 60 seconds. Relative mRNA expression was normalized to the expression of HPRT housekeeping gene [36].

and after the incubation) was measured using a microplate
spectrophotometer (Winooski, VT) at an excitation of 494 nm.

Preparation of HMGB1 proteins
Recombinant HMGB1 was expressed in E. coli and purified to
homogeneity, and endotoxin was extracted with triton X-114
[10,33]. Redox-modified HMGB1 proteins were made as previously described [19,34]. The LPS content in HMGB1 protein
preparations was verified to be less than 10 pg/mg protein using
Chromogenic Limulus Amebocyte Lysate Assay (Lonza Inc.,
Walkersville, MD).

Cytokine measurements
TNF and IL-6 released in the cell culture supernatants were
measured by ELISA as per manufacturer’s instructions (R & D
System Inc., Minneapolis, MN). HMGB1 levels were measured by
western blot or ELISA [11].

Cytotoxicity of DNA beads
Human cervical cancer cell line Hela and human epithelial
colorectal adenocarcinoma cell line Caco-2 were incubated with
increasing concentrations of control beads or with B2 DNA-beads
for various time periods at 37uC. Cell death was determined by
analyzing levels of lactate dehydrogenase (LDH) in the supernatant using LDH cytotoxicity kit. Triton X-100 (2%) was used as a
positive control.

Surface plasmon resonance analysis
Binding of HMGB1 to DNA molecules was analyzed by surface
plasmon resonance analysis using the BIAcore T200 instrument
(BIAcore Inc, NJ). Recombinant HMGB1 was immobilized on a
CM5 dextran sensor chip, and different concentrations of DNA
(S1 or S2, 0–10 mM) were used as analyte. The association of
analyte and ligand was recorded using surface plasmon resonance
and the results were analyzed using BIAeval 3.2 software.

Capture of HMGB1 using DNA beads from biological
samples in vitro

Stability of DNA beads

RAW 264.7 cells in 6-well plates were stimulated with LPS
(100 ng/ml) for 16 hours to induce the release of HMGB1. The
cell supernatant was concentrated 106using Microcon centrifugal
filters, and incubated with B1, B2 or control beads (100 ml
supernatant/20 ml beads) at room temperature for an hour with
gentle rotation. Bound and free HMGB1 levels were measured by
western blot.

To determine stability of DNA beads in acidic conditions, DNA
beads (B1, B2 or B3, 20 ml) were incubated with 500 ng of
HMGB1 in PBS (pH 7.0) or HCl (pH 1 or 2) for an hour at room
temperature. In addition, susceptibility to DNase I-mediated
digestion was evaluated by pretreating DNA beads B2 with a
biological concentration of DNase I (40 ng/ml) for 30 minutes at
37uC [35] prior to incubation with of HMGB1 (0, 0.01, 0.1, 0.2,
0.5, 1, 2, 3 mg/5 ml beads) for 1 hour at room temperature. After
washing beads with PBS, HMGB1 bound to the beads was eluted
and measured by western blot.

Animals
Female IL-10 knockout (KO) mice on C57BL/6J background
(12 weeks old, stock #002251) were purchased from JAX
laboratory (Bar Harbor, ME). Female and male C57BL/6J or
BALB/c (8–12 weeks old) mice were purchased from Taconic
laboratory (Germantown, NY). Mice were housed in the Feinstein
Institute for Medical Research Animal Facility under standard
temperature, and light and dark cycle. All animal procedures were
carried out in strict accordance with the recommendations in the

Immunogenicity of DNA oligos and DNA beads
Human primary macrophages were stimulated with HMGB1
(1 mg/ml) or LPS (2 ng/ml) in the presence or absence of S1, S2 or
S3 DNA (1 mM or as indicated) at 37uC for 16 hours. TNF levels
were measured in the supernatant. In separate experiments,
PLOS ONE | www.plosone.org
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length colon was collected, and its weight measured. Blood, feces
and colon tissues were harvested for analysis.

Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. The protocol was approved by the
Institutional Animal Care and Use Committee of the Feinstein
Institute for Medical Research at North Shore-LIJ Health System
(Animal Welfare Assurance number A-3168-01). Acute colitis was
induced by feeding female BALB/c mice with 4% DSS dissolved
in drinking water ad libitum for five days, followed by normal
water for three days. Animals were euthanized after overnight
fasting on day 9 [13,14,17]. For chronic colitis model, IL-10 KO
mice were monitored for development of colitis.

Histology
Colon tissues were fixed in 10% formalin and embedded in
paraffin. Five-mm hematoxylin and eosin (H&E) stained sections
were prepared by AML laboratory (Baltimore, MD). Colitis scores
were determined for each high power view (magnification 406)
and 10 fields were viewed for each sample. The histological
scoring system to quantify the degree of colitis was described
previously and was evaluated in a blinded fashion [37]. The score
ranged from 0 to 14 and was defined as follows. The inflammation
severity was scored as 0–3 (0, no sign of inflammation; 1, mild
inflammation; 2, moderate inflammation; 3, severe inflammation).
The inflammation extent was graded from 0 to 3 (0, no
inflammation; 1, mucosa; 2, mucosa and submucosa; 3, transmural). Crypt damage was scored as 0 to 4 (0, no damage; 1, basal 1/
3 damage; 2, basal 2/3 damage; 3, crypts loss with presence of
surface epithelium; 4, loss of both crypts and surface epithelium).
Percentage of involvement was defined as 0 to 4 (0, 0%; 1, 1–25%;
2, 26–50%; 3, 51–75%; 4, 76–100%). The 10 data points for each
mouse were averaged and colon inflammation score was expressed
as means 6 SEM.

Colon tissue explants cultures
For ex vivo culture of the colon, full length colons from normal
C57B/L6 mice were isolated, both ends tied and incubated with
HMGB1 or PBS (in 0.5 ml volume) at room temperature with
gentle shaking. After 1 hour incubation, LDH content was
measured in the colonic suspension. In separate experiments,
full-length colons were isolated from individual DSS-colitis mice,
tied at both the ends and incubated with 0.5 ml of 50% B1 or B2
beads at room temperature for two hours with gentle shaking. The
beads were harvested, washed thoroughly with PBS and analyzed
by western blot.

Ex vivo capture of HMGB1 from serum samples of septic
mice, and fecal samples from colitis mice

Quantitative PCR analysis of colonic cytokine expression

Male, C57 BL/6 mice (8–12 weeks of age) were subjected to a
cecal ligation and puncture (CLP) procedure [11]. Serum samples
were collected from CLP and control mice after 48 hours, and
incubated with 20 ml of B1, B2 or control beads at room
temperature for an hour. Bound and free HMGB1 levels were
analyzed on beads and supernatant using western blot and ELISA
respectively. In separate experiments, fecal samples from DSScolitis colons were gently flushed out with cold PBS containing 16
protease inhibitor, and the suspension was rotated for an hour at
room temperature in the presence of gentamycin and imipenum.
After centrifugation to remove fecal debris, fecal extract containing 40 mg of total protein was incubated with B1, B2 or control
beads at room temperature for an hour. Bound HMGB1 on beads
was analyzed after washing the beads with PBS by western blot.

Two 0.5 cm segments, one from the proximal and the distal end
of each colon tissue, were mixed together for RNA extraction
using QIAzol Lysis Reagent. The levels of IL-6 and IL-1b mRNA
were analyzed by quantitative PCR using a one-step RT-PCR kit
and a Roche Light Cycler 480 Instrument. Primers sequences used
in PCR amplification were as follows: IL-6 forward 59GCTACCAAACTGGATATAATCAGGA39 and reverse 59CAGGTAGCTATGGTACTCCAGAA39; IL-1b forward 59AGTTGACGGACCCCAAAAG39 and reverse 59AGCTGGATGCTCTCATCAGG39. The PCR amplification was performed by
denaturing the samples at 95uC for 10 minutes, followed by 45
cycles, each cycle consisting of denaturing at 95uC for 10 seconds,
annealing at 60uC for 30 seconds, and an extension at 72uC for
60 seconds. Relative mRNA expression was normalized to the
expression of HPRT housekeeping gene [36].

Analysis of HMGB1 isoforms by liquid chromatography
and mass spectrometric analysis (LC-MS/MS)

Statistical analysis
Data are presented as means 6 SEM. Differences between
groups were determined by using student’s t test, one-way
ANOVA followed by the least significant difference test. P values
less than 0.05 were considered statistically significant.

HMGB1 from colitis fecal samples was captured using DNA
beads, and eluted using 8M urea. HMGB1 in the eluted samples
were confirmed by western blot analysis. Cell lysate from intestinal
epithelial (Caco 2) cells was used as control for intracellular
HMGB1. Analysis of LC-MS/MS was performed at Liverpool,
UK. Samples were subjected to digestion by trypsin (Promega,
Madison, WI) or endopeptidase GluC (New England Bio Labs.,
Ipswich, MA) according to the manufacturer’s instructions.
Characterization of cysteine bonds and absolute quantification of
acetylated HMGB1 was determined as described previously
[24,25].

Results
DNA oligos are inert and neutralize HMGB1-mediated
macrophage activation
Initially we chose four DNA oligo sequences that bind to
HMGB1 with high affinity [28–30,38]. To determine whether
DNA oligos induce inflammatory responses, we incubated human
macrophages with DNA oligos S1, S2, S3 or S4 (1 mM) or with
HMGB1 (1 mg/ml), and measured TNF release. None of the DNA
oligos increased TNF release, suggesting that these DNA oligos
themselves are inert and do not induce inflammatory responses
(Fig. 1A). Next, we sought to determine whether DNA oligos can
selectively neutralize HMGB1-mediated inflammatory responses.
When primary human macrophages were stimulated with
HMGB1 or LPS, the addition of DNA oligos S1, S2, S3 and S4
significantly inhibited HMGB1-induced, but not LPS-induced,
TNF release in a concentration-dependent manner (Fig. 1B–C).

Oral administration of DNA beads in colitis mice
B2, B4 or control beads (300 ml of 50% slurry) were orally
administered to female BALB/c (10–12 weeks old) on days 0, 1, 2,
4 and 6 after DSS administration or to IL-10 KO mice starting at
12 weeks of age (when they spontaneously develop IBD). BALB/c
mice were euthanized on day 8 after DSS, and IL-10 KO mice
received B2 beads once every other day for a total of six weeks.
Body weight was monitored daily (for BALB/c mice) or every
other day (for IL-10 KO mice). At the time of euthanization, full
PLOS ONE | www.plosone.org
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HMGB1 (2 mg) in a concentration-dependent manner (Fig. 2A).
DNA beads B1, B2 and B3 were most effective, capturing more
than 90% of the HMGB1. Control beads (containing no DNA)
and B4 beads (composed of kinked duplex DNA) failed to bind
HMGB1, and both served as non-HMGB1 binding controls for
subsequent experiments (Fig. 2A). Next, to determine the binding
capacity of DNA beads, fixed amount of DNA beads (B1, B2 and
B3) was incubated with increasing concentrations of HMGB1.
Western blot analysis of free and bound HMGB1 revealed that
DNA beads bind to HMGB1 in a concentration dependent
manner with an approximate binding capacity of 1 mg HMGB1
per 50 ml DNA beads (Fig. 2B). The binding ratio of HMGB1 to
DNA beads was calculated based on the maximum binding of
HMGB1 to a constant amount of DNA beads; HMGB1 binds to
DNA beads with approximate molar ratios of 6:1 for B1 and B2,
and 12:1 for B3 beads. To elucidate the binding kinetics, DNA

To test whether free DNA oligos act synergistically with bacterial
endotoxin (lipopolysaccharide, LPS) as this might occur in the gut
microenvironment, we stimulated primary human macrophages
with LPS in the presence of increasing concentration of DNA
oligos. Notably, DNA oligos did not synergistically act with LPS to
enhance LPS-induced macrophage activation (Fig. 1C). Together,
these results indicate that DNA oligos specifically neutralize
HMGB1-mediated macrophage activation.

Binding of DNA beads to HMGB1
Next we conjugated the oligos to sepharose beads. Beads bound
to S1, S2, S3 and S4 oligos are referred as B1, B2, B3 and B4 as
described in methods. To study the binding characteristics of DNA
oligos to HMGB1, we incubated recombinant HMGB1 with
increasing amounts of DNA beads, and analyzed bound HMGB1
by western blot analysis. B1, B2 and B3 DNA beads bind to

Figure 1. S1, S2, S3 and S4 DNA are inert and inhibit HMGB1, but not LPS-induced TNF release from macrophages. A) S1–S4 DNA is
inert. Primary human macrophages were incubated with HMGB1 (positive control) or S1–S4 DNA (1 mM) for 16 hours. TNF released in the
supernatants was measured by ELISA. Data are mean 6 SEM from 3 experiments. B) S1–S4 DNA inhibits HMGB1-induced TNF release from cultured
macrophages. Primary human macrophages in 96-well culture plates were stimulated with HMGB1 and various amounts of DNA as indicated for
16 hours. TNF released in the supernatants were measured by ELISA. N = 3 independent experiments. *: p,0.05 vs. HMGB1 alone. C) S1–S4 DNA does
not inhibit LPS-induced TNF release. Primary human macrophages in 96-well culture plates were stimulated with LPS (2 ng/ml) plus increasing
amounts of S1–S4 DNA overnight at 37uC. TNF released was measured. N = 3 experiments.
doi:10.1371/journal.pone.0103992.g001
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beads were incubated with HMGB1 for different times. DNA
beads B1 and B2 beads bind HMGB1 by 15 min, with maximal
binding observed by 30 minutes. In contrast, DNA beads B3
achieved saturation within 15 minutes (Fig. 2C). Based on these
findings, we have carried out 1 hour incubation period for our
subsequent binding assays to remove HMGB1 from biological
samples.

DNA beads B1 and B2 sequester different isoforms of
HMGB1 but not histone protein H3 or TNF
HMGB1 contains three conserved redox-sensitive cysteines
(C23, C45 and C106) that determine the biological activity of
extracellular HMGB1 [19–22] (Fig. 3A). In this context, the fully
reduced form of HMGB1 dominates intracellular HMGB1 pool,
whereas macrophage activation markedly induces the formation of

Figure 2. B1–B3, but not B4 beads bind to HMGB1. A) Depletion curve of HMGB1 binding to various DNA beads. Recombinant HMGB1 (2 mg
per reaction) was mixed with a range of concentrations of different types of DNA beads as indicated and incubated at room temperature for two
hours. The mixture was then centrifuged at 2,000 rpm for five minutes to precipitate the beads. Beads were then washed five times with PBS. Both
supernatants and elute from beads were subjected to western blot analysis probed with anti-HMGB1 antibody. B) Saturation curve of HMGB1 binding
to various DNA beads. Fixed amounts (20 ml drained beads) of B1–B3 or control beads were incubated with increasing amounts of HMGB1 (in 50 ml
volume) at concentrations indicated for two hours at room temperature with rotation. The mixture was then centrifuged at 2,000 rpm for five
minutes to precipitate the beads. The supernatants were aspirated, both supernatants and elute from beads were subjected to western blot for
HMGB1 measurement using monoclonal anti-HMGB1 antibodies. The binding of 1 mg HMGB1 requires about 0.4 ng (B1 and beads) or 2.8 ng (B3) in
beads, respectively. C) Time-course of HMGB1 binding to various DNA beads. B1–B3 beads (20 ml) were incubated with 500 ng of HMGB1 (50 ml total
volume) at room temperature for the time periods indicated. HMGB1 bound to the beads was revealed by western blot analysis. Data are
representative from 3–4 separate experiments.
doi:10.1371/journal.pone.0103992.g002
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Figure 3. DNA beads bind to HMGB1 isoforms but not TNF or histone H3. A) Schematic representation of fully reduced, disulfide and
sulfonyl forms of HMGB1 and their biological functions. B) DNA beads bind to disulfide HMGB1 in feces from colitis mice. The redox state of HMGB1
captured by DNA beads B1 or B2 from feces of colitis mice was assessed by trypsin digestion followed by LC/MS analysis. Cell lysate from colorectal
epithelial (Caco 2) cells was used as control for intracellular HMGB1. Diagnostic peptides showed with the presence of molecular weights 1496 and
550 (Da) indicates reduced cysteines 23 and 45 respectively, whereas the appearance of molecular weights of 1564 and 618 (Da) indicates forming of
an intramolecular disulfide linkage between cysteines 23 and 45 (arrows). Cys 106 (MW = 2002) is in reduced form in all samples presented here. Data
are representative from two separate experiments. C) DNA beads bind to hyper-acetylated form of HMGB1 in feces from colitis mice. Representative
spetra of the LC-MS traces of the above samples digested with endopeptidase GluC. The presence of peptides with molecular weights 1624 and
1132 Da (arrows) indicates the hypo-acetylation of lysine residues in NLS1 and NLS2 regions respectively; whereas the presence of peptides of 1749
and 1342 Da (arrows) indicates hyper-acetylation of lysines within NLS1 and NLS2 regions. Data are representative from two separate experiments. D)
B2 beads bind to redox modified HMGB1 proteins. Increasing amounts of various HMGB1 proteins (100 or 250 ng) were added to B2 beads (20 ml)
and the mixture (50 ml total volume) was incubated at room temperature for two hours. The mixture was then centrifuged and HMGB1 bound to
beads were revealed by western blotting with anti-HMGB1 antibodies. N = 3 experiments. E) B2 beads do not bind to TNF. To examine the specificity
of DNA beads and HMGB1 binding, human TNF (200 ng) was incubated with increasing amounts of B2 beads (as indicated) at room temperature for
two hours. After incubation, TNF remaining in the supernatants and bound to the beads were analyzed by western blot probed with anti-human TNF
antibodies. Data are representative from three separate experiments. F) B2 beads do not bind to human histone H3. B2, B1 or control beads (5 ml) in
each tube were incubated with increasing amounts of human histone H3 (0, 0.01, 0.1, 0.2, 0.5, 1, 2, 3 mg) for two hours at room temperature. The
amount of histone H3 bound to DNA beads was analyzed by western blot using anti-histone H3 antibodies. Histone H3 protein was used as a positive
control in western blot. Data are representative of 3 repeats.
doi:10.1371/journal.pone.0103992.g003

induce cell toxicity resulting in reduced inflammatory responses.
To investigate this possibility, Caco-2 cells or Hela (human
cervical cancer cell line) cells were cultured with B2 beads.
Analysis of secreted cell death marker, lactate dehydrogenase
(LDH), demonstrated that LDH levels were not significantly
different between Caco-2 cells exposed to different amounts of B2
or control beads for increasing incubation periods compared with
medium alone (Fig. 4A). The non-toxic effects of beads were
further confirmed by exposing Hela cells to B2 beads (data not
shown).

HMGB1 bearing disulfide bonds between Cys23 and Cys45 [24].
It is theoretically possible that in IBD, cell death and activation of
immune cells may contribute to accumulation of different isoforms
of HMGB1. Specifically, cell death by necrosis may lead to passive
release of fully reduced HMGB1, whereas cell activation may
result in active release of disulfide HMGB1. To test this
hypothesis, HMGB1 was sequestered from colitis feces using
DNA beads. HMGB1 captured by DNA beads was further
subjected to liquid chromatography and mass spectrometric
analysis (LC-MS/MS) to assess redox form and acetylation status
as described previously [24,25]. As expected, HMGB1 captured
by B1 or B2 beads from feces of colitis mice contained a mixture of
pro-inflammatory isoforms (cytokine-inducing disulfide HMGB1
and fully reduced HMGB1). As control, we also analyzed HMGB1
extracted from cultured human colorectal epithelial adenocarcinoma Caco-2 cell line, confirming the fully reduced intracellular
form of HMGB1 (Fig. 3B). It has been established that HMGB1
released by cell activation is hyper-acetylated. In contrast,
HMGB1 released by cell death is hypo-acetylated [23,24].
HMGB1 from colitis feces and captured by DNA beads was
hyper-acetylated in both nuclear localization sequences (NLS1 and
NLS2) (Fig. 3C). In contrast, HMGB1 isolated from Caco 2 cells
was hypo-acetylated, implicating the active and passive release of
HMGB1 respectively. Next, to confirm the binding of DNA beads
to different isoforms of HMGB1, we generated different redox
forms of HMGB1 by exposing HMGB1 to either hydrogen
peroxide or dithiothretol as described previously [19] prior to
incubation with DNA beads. B1 and B2 beads bind to all three
redox-modified HMGB1 proteins in a concentration-dependent
manner (Fig. 3D). Taken together, B1 and B2 beads can sequester
different redox and acetylated forms of HMGB1 found in the fecal
environment of colitis animals. It is also theoretically plausible that
DNA beads may exhibit non-specific interaction with either other
DNA binding proteins including histones or other inflammatory
mediators present in fecal samples. To elucidate this possibility, we
incubated DNA beads (B1, B2 and control beads) with TNF or
histone H3 (one of the core histones). Western blot analysis of free
and bound protein revealed that both control and DNA beads
failed to bind to significant amounts of either TNF or histone H3
(Fig. 3E and 3F).

Neutralizing effects of DNA beads are independent of
type 1 interferon (IFN) expression
Previous studies showed that increased expression of type 1 IFN,
induced by stimulation with self or non-self DNA, protects mice
from experimental colitis [39]. Type 1 IFN has been evaluated in
pilot clinical trials for the treatment of active ulcerative colitis
[40,41]. Based on these studies, it is possible that the inhibitory
effects of DNA beads are mediated via the production of Type I
IFN. To test this possibility, we measured type 1 IFN mRNA levels
in the presence of oligos or DNA beads using quantitative PCR.
Oligos (S1 and S2) and DNA beads (B1 and B2 beads) failed to
induce type I IFN mRNA expression in RAW 264.7 cells, whereas
LPS or poly I:C induced IFN expression (positive controls)
(Fig. 4B). These results further confirm previous observations that
the DNA oligos used in these studies are inert and do not induce
inflammatory phenotype in macrophage population [30].

DNA beads are stable in various biological conditions
To examine the stability of DNA-coated sepharose beads in
biological fluid at body temperature, we used fluorescent FAMlabeled DNA coated beads. The FAM-labeled DNA beads were
incubated with fecal extract at 37uC for two hours and the
amounts of free DNA in the supernatant were evaluated. There
were no significant differences in the amount of fluorescent DNA
released in the supernatant between beads exposed to fecal extract
or not (Fig. 5A) [42]. Next, to evaluate whether HMGB1 binding
ability of DNA beads remain intact under different pH conditions,
DNA beads were incubated with HMGB1 at neutral or acidic pH;
all three beads (B1, B2 and B3) efficiently captured HMGB1 from
solutions in a concentration-dependent manner. Notably, only B1
and B2 beads, but not B3 beads, retain the binding capacity at
pH 1 or 2 (Fig. 5B). This feature is an advantage as DNA beads
will be administered orally in colitis mice and exposed to the acidic

DNA beads do not affect cell viability
We have demonstrated that S1, S2, S3 and S4 oligos selectively
neutralize HMGB1 mediated inflammatory responses (Fig. 1B). It
is theoretically plausible that incubation with DNA beads may
PLOS ONE | www.plosone.org
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Figure 4. DNA beads are neither cytotoxic nor able to induce type I IFN expression. A) B2 DNA beads are not cytotoxic. Caco-2 (human
epithelial colorectal adenocarcinoma) cells in 24-well plates were incubated with increasing amounts of B2 or control beads overnight at 37uC in OptiMEM medium. In time course experiments, fixed amount of B2 or control beads (5 ml) were incubated with cells for the time periods indicated.
Supernatants were collected and LDH levels were analyzed by cytotoxicity kit. Triton X-100 (2%) was used as a positive control. Data are means 6
SEM, N = 3 experiments. B) DNA beads do not induce type I IFN expression in macrophages. RAW 264.7 cells were incubated with LPS (2 ng/ml) or
poly I:C (1 mM, positive controls), S1, S2 or B1, B2 beads for 24 hours at 37uC. Cell total RNA was extracted; the expression IFN-b and HPRT mRNA was
analyzed by quantitative PCR and presented as the ratio of IFN-b/HPRT. N = 3–4 per group. *: p,0.05 vs. medium alone.
doi:10.1371/journal.pone.0103992.g004

environment of the stomach. In addition, we determined whether
DNA bound to the beads is susceptible to DNAse I mediated
digestion. B2 beads were incubated with physiological concentration of DNase I (40 ng/ml) [35] prior to incubation with
recombinant HMGB1. Pre-exposure to DNase I did not alter
the binding efficiency of B2 beads to HMGB1 suggesting that
bound DNA is resistant to DNase I; presumably protected by their
phosphorothioated backbones (Fig. 5C).

PLOS ONE | www.plosone.org

Intraluminal HMGB1 induces tissue damage
Analysis of the focal concentration of HMGB1 in the colon have
demonstrated that HMGB1 is released by colonic tissue in animal
models of colitis [14,17,18]. Based on our previous findings that
HMGB1 increases the permeability of human epithelial cells and
that neutralization of HMGB1 ameliorates gut barrier dysfunction
[15,16], we hypothesized that intralumenal HMGB1 might
mediate intestinal epithelial dysfunction and contribute to
intestinal inflammation. To test this hypothesis, we infused freshly
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Figure 5. DNA beads are stable. A) B2 DNA beads are stable in fecal matters. Fluorescent FAM-labeled B2 beads (50 ml) was incubated with fecal
extract of colitis mice (300 ml) for 2 hours at 37uC. After centrifugation, beads were washed five times with PBS and re-suspended as 50% slurry. The
fluorescence intensity in both supernatants and beads (before and after the incubation) was measured by using a microplate spectrophotometer at
excitation of 494 nm. N = 3 separate experiments. B) B1 and B2 beads are resistant to acidic pH, B3 is not. B1, B2 or B3 beads at the amounts indicated
were incubated with HMGB1 (500 ng) in either solutions of PBS (pH 7) or HCl (pH 2 or 1) at room temperature for 2 hours. HMGB1 bound to the
beads was revealed by western blot analysis. Data are representative from 3 separate experiments. C) B2 beads are resistant to degradation by DNase
I. DNA beads were incubated with DNase I (40 ng/ml, a concentration observed in biological fluid [35]) for 30 minutes at 37uC. The binding of HMGB1
by B2 beads with or without DNase I treatment was analyzed by western blot. Data are from 3 separate experiments.
doi:10.1371/journal.pone.0103992.g005

isolated mouse colon segments with HMGB1 or vehicle PBS.
HMGB1 infused in the colon resulted in a 2–3 fold increase in
LDH release, a marker of epithelial damage, as compared to PBS
controls (Fig. 6A), indicating that intraluminal presence of
HMGB1 acts as a mediator of epithelial damage.

PLOS ONE | www.plosone.org

DNA beads bind and remove HMGB1 from inflamed
colon and feces
HMGB1 levels are increased in inflamed colons and in feces
with both human and murine colitis [13,14,17,18]. To demonstrate that the fecal micro-environment did not interfere with
binding of HMGB1 to DNA beads, we first analyzed HMGB1
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Figure 6. HMGB1 causes increased intestinal LDH release; and DNA beads capture HMGB1 in biological fluids ex vivo. A) HMGB1 (10
and 30 mg/ml) or PBS (all in 500 ml volume) were injected into freshly isolated full length colons from mice and incubated at room temperature for
1 hour. Colonic lavage was collected and LDH levels were measured. N = 3 preparations per group. *: p,0.05, **: p,0.01 vs. PBS group. B) DNA beads
capture HMGB1 from feces of colitis mice induced by DSS. Feces in the colon of colitis mice were gently flushed out with cold PBS containing 16
protease inhibitor, and the suspension was rotated for an hour at room temperature in the presence of gentamycin and imipenum. After
centrifugation to remove fecal debris, fecal extract containing 40 mg of total protein was incubated with B1, B2 or control beads at room temperature
for an hour. After washing with PBS, beads were boiled and eluate was analyzed by western blot probed with anti-HMGB1 antibodies. N = 3–4 mice
per group. *: p,0.05 vs. DSS control. C) Female BALB/c mice (8–12 weeks old, n = 10–12 per group) were given 4% dextran sodium sulfate (DSS)
dissolved in drinking water ad libitum for five days, and then switched to normal water for three days. DNA beads capture HMGB1 from inflamed
colon from colitis mice. Mice were euthanized on day 9th after overnight fasting. Both B1 and B2 beads captured HMGB1 from colon culture of colitis
mice (see Methods) compared to control beads. D) DNA beads remove HMGB1 from septic mice sera. Serum (20 ml) from normal or septic mice was
incubated with 50 ml of B2 or control beads at room temperature for an hour. Samples were then centrifuged at room temperature for five minutes.
The binding of DNA beads with HMGB1 was measured using western blot or ELISA. Data shown are means 6 SEM from 3–5 mice per group. *: p,
0.05 vs. control beads. E) DNA beads capture HMGB1 from cell supernatants. RAW 264.7 cells in 6-well plate were stimulated with LPS (100 ng/ml) for
16 hours, and HMGB1 containing supernatant (1 ml) was collected and concentrated 106 through centrifugation with Microcon centrifugal filters.
The concentrated RAW 264.7 cell supernatant was then incubated with beads (20 ml) containing control, B1 or B2 beads at room temperature for an
hour with rotation. HMGB1 content in both supernatant and beads were measured by western blot. N = 2 repeats each performed in duplicate.
doi:10.1371/journal.pone.0103992.g006

beads did not (Fig. 6B). Next, we performed an ex vivo colon
cultures with colons isolated from mice subjected to DSS-induced
colitis. B1, B2 or control beads were infused in the colons isolated
from DSS-induced colitis mice. B1 and B2 beads captured
significant amounts of HMGB1 from ex vivo colon culture

captured by B2 beads in the presence and absence of fecal debris.
BALB/c mice were subjected to DSS to induce colitis as described
in Methods. B2 beads (20 ml) were added directly to fecal matters
obtained from these colitis mice. B1 and B2 beads (20 ml) captured
HMGB1 from the feces extracts from colitis mice whereas control
PLOS ONE | www.plosone.org
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HMGB1 (HMGB1 = 5664 in B4 beads group vs. 5062 ng/ml in
control beads group. N = 9–10 mice per group, p = N.S.).
In agreement with the findings in DSS-induced colitis model,
administration of B2 beads significantly improved disease pathogenesis in IL-10 knockout (KO) mice with spontaneously
developed colitis. Oral administration of B2 beads significantly
increased body weight compared to control beads or unmanipulated group after 6 weeks of treatment (final body weight = 2362 grams in B2 beads group, 1962 or 1863 grams in untreated or
control beads groups respectively. N = 5 or 7 mice per group, *p,
0.05 B2 beads vs. control beads group, Fig. 8A). Consistent with
these findings, the IL-10 KO mice receiving B2 beads exhibited a
significant reduction in serum HMGB1 levels, and lower levels of
colonic IL-6 and IL-1b expression as compared to control beads
group (Fig. 8B). These changes were also reflected in the severity
of colon injury. Gross inspection of the colon revealed decreased
swelling in mice treated with B2 beads, as compared to mice
treated with control beads. Histological evaluation demonstrated
severe thickening of the colon walls in groups of untreated or
control beads-treated mice; significantly less thickening was
observed with administration of B2 beads (histological
score = 3.560.8 in B2 beads group, and 7.260.9 or 9.061.4 in
untreated or control beads treated groups respectively. p,0.05, B2
beads vs. control beads groups. Fig. 8C). Taken together, HMGB1
plays an important role in mediating disease severity in colitis, and
sequestering HMGB1 using HMGB1-binding DNA beads significantly attenuate disease pathogenesis in animal models of colitis.

compared to control beads (Fig. 6C). Taken together, these
observations demonstrate that HMGB1 levels are elevated locally
in the colonic micro-environment, and DNA beads can be utilized
to sequester and reduce HMGB1 levels from colitis colon.

DNA beads bind and remove HMGB1 from septic mouse
serum
Circulating HMGB1 levels are elevated in many inflammatory
disease conditions including sepsis [10,11,43,44].To test whether
DNA beads capture and remove HMGB1 in the serum, we
utilized an established model of murine sepsis induced by cecal
ligation and puncture (CLP) [11,45]. In this model, a surgically
created diverticulum of the cecum is punctured. This procedure
reproducibly results in elevated serum HMGB1 levels compared to
normal controls (Fig. 6D) [11]. When serum samples containing
high levels of HMGB1 were incubated with B2 or control beads
(20 ml), B2 beads but not the control beads sequestered significant
amount of HMGB1 from septic serum. In agreement with these
findings, HMGB1 bound to the B2 beads was significantly higher
than that bound to the control beads (Fig. 6D), suggesting that
DNA beads are capable of removing HMGB1 from biological
samples ex vivo.

DNA beads sequester HMGB1 ex vivo from activated cell
supernatants
Next we investigated whether DNA beads can efficiently
sequester HMGB1 from biological samples. RAW 264.7 cells
were stimulated with LPS to induce release of HMGB1 in cell
supernatant [10]. B1 and B2 beads efficiently bound and removed
HMGB1 from the activated RAW cell supernatants while control
beads did not (Fig. 6E). B3 beads failed to bind HMGB1 in cell
supernatants and were eliminated from further in vivo studies. As
B2 beads consistently showed greater binding to HMGB1 than the
other DNA constructs in ex vivo studies, it was chosen for the
subsequent in vivo studies.

Discussion
Together, these findings establish that the DNA beads can
selectively sequester HMGB1 from colitis colons and improve
disease pathophysiology in experimental models of colitis. Initially
identified as a nucleosomal protein, cytokine inducing activities of
HMGB1 are now well established. HMGB1 is secreted by many
cell types and specifically stimulates synthesis of proinflammatory
cytokines by monocytes and macrophages [12,32,47,48]. It acts as
a necessary and sufficient mediator of sepsis pathophysiology
[12,49,50]. Neutralization of HMGB1 using anti-HMGB1 antibodies or HMGB1-specific antagonists have been successfully
ameliorated disease severity in many experimental disease models
[11,32,47]. Ample evidence indicates that HMGB1 is an
important mediator in the pathogenesis of colitis and colitis
associated carcinoma [13,17]. Increased circulating levels of
HMGB1 have been observed in animal models of IBD and are
positively associated with disease severity [13]. Fecal HMGB1 is a
novel marker of intestinal mucosal inflammation with important
implications in the pathogenesis of human IBD [51]. HMGB1 is
secreted by inflamed human intestinal tissues, and abundantly
found in stools of IBD patients [14,18]. It is established that high
levels of HMGB1 increase epithelial cell permeability and impair
intestinal barrier function [15]. Together these studies suggest that
HMGB1 is an important target in IBD, and sequestration and or
neutralization of HMGB1 would be beneficial for controlling the
disease severity in colitis. Here we utilized the strong DNA binding
property of HMGB1, and developed DNA beads that selectively
bind and sequester HMGB1 from biological fluids.
Recent studies emphasize that during tissue inflammation and
repair, HMGB1 is present in different redox states in the
extracellular environment. The redox states of the three conserved
cysteine residues within HMGB1 regulate its receptor-binding
ability and subsequent biological outcome [12,32,47]. Given the
importance of presence of various redox forms of HMGB1, we
assessed the potential binding of DNA beads to different isoforms

DNA beads B2 ameliorates inflammation in animal
models of acute and chronic colitis
Reasoning that administration of DNA beads might ameliorate
inflammation in colitis conditions; we examined the effects of
DNA beads in models of both acute (DSS-induced colitis) and
chronic colitis (IL-10 KO mice that spontaneously developed
colitis [46]). Oral administration of B2 beads to mice with DSSinduced colitis significantly improved weight loss compared to
animals receiving control beads (weight change = 20.860.4 gm/8
days in B2 beads group and 23.860.5 gm/8 days in control
beads groups, respectively. *p,0.05. Fig. 7A–B). We observed
that animals receiving B2 beads also had significantly lower levels
of circulating and fecal HMGB1 (Fig. 7B), decreased colonic wall
thickening as revealed by less tissue swelling, recovery of crypt
structure (Fig. 7C), and significantly improved histological scores
for the colon compared to control beads-treated group
(scores = 3.862.1 in B2 beads group vs. 10.861.8 in control
beads groups. p,0.05. N = 10 per group. Fig. 7B–C). To confirm
the specificity of HMGB1-binding DNA beads in mediating
improvement of colitis, we administered B4 beads as control beads
to DSS-colitis mice. Our prior analysis has demonstrated that B4
beads failed to sequester HMGB1 (Fig. 2A). As expected,
administration of B4 beads did not improve DSS-induced weight
loss in mice (the body weight change = 23.060.4 in B4 beads
group vs. 22.660.3 gram/8 days in control beads group; N = 9–
10 mice/group. P = N.S.), and did not reduce circulating levels of
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Figure 7. Administration of B2 beads ameliorates inflammation in DSS-induced colitis in mice. Female BALB/c mice (10 mice per group)
were given 4% DSS in drinking water to induce colitis water for 5 days to induce colitis, and then switched to normal water. Mice were orally
administrated with 300 ml (50% slurry, gavage) of B2 or control beads on days 0, 2, 4 and 6 after DSS initiation and were euthanized on day 8. A)
Treatment with B2 beads reduced body weight loss in DSS-induced colitis mice. *: p,0.05 vs. control beads group. B) Body weight change, colon
measurements (weight and length) and levels of serum and fecal HMGB1 in colitis mice treated with B2 or control beads. *: p,0.05 vs. control beads
group. C) Histological evaluation of B2 or control beads treated colitis mice. Representative H&E staining of colons from normal, control or B2 beadstreated colitis mice is shown. Histological scores of colons are shown. N = 10 mice per group. *: p,0.05 vs. control beads group. Magnification: 640.
doi:10.1371/journal.pone.0103992.g007

of HMGB1. Our in vitro assessments of redox-modified recombinant HMGB1 showed that DNA beads dose dependently
sequester different isoforms of HMGB1. An interesting question
is whether any specific redox isoform of HMGB1 is predominantly
present during active phase of colitis. To this end, we have
analyzed the redox status of HMGB1 sequestered from colitis fecal
material using DNA beads. As expected, fecal HMGB1 captured
by DNA beads contained a mixture of redox isoforms including
cytokine-inducing disulfide HMGB1 and chemotaxis-inducing
fully reduced HMGB1. We found that the predominant form of
HMGB1 is the disulfide isoform suggesting a role of HMGB1 in
mediating and perpetuating mucosal inflammation. It is noteworthy that HMGB1 specific receptors, TLR4 and RAGE, are upregulated in colon tissues in colitis environment [18], implicating
the importance of identifying a treatment strategy that will
effectively sequester and neutralize different isoforms of HMGB1
in IBD.
The objective of this study was to develop HMGB1 specific
DNA beads that could abrogate disease in murine models acute
and chronic colitis, and thus have a potential as a therapy for
human IBD. We have now demonstrated that administration of
PLOS ONE | www.plosone.org

DNA beads significantly ameliorated the disease severity associated with improvement in clinical measures of colitis, including
body weight loss; morphological parameters such as colon weight;
inflammatory markers, and histological scores for colonic tissue
injury. We did not observe toxicity in animals treated with either
DNA beads or the control beads, and we found that the
neutralizing effect of DNA beads is independent of type 1 IFN
expression. Another important finding in our study is that DNA
beads bind specifically to HMGB1, and not to other proteins,
including DNA binding protein histone H3. Although histone H3
(one of the core histones and a DAMP prototype) failed to bind to
DNA beads in our experiments, which may attribute to the
requirement of specific sequence and length of (146 bp for core
histones) of DNA for binding to histones [52], we cannot exclude
the possibility that other proteins may also bind to DNA beads.
DNA beads may bind to HMGB2 and HMGB3 [9], histones H1
and B4 and hyaluronic acid. However, none of these DNA
binding proteins are present in significant amounts in the
gastrointestinal tract.
In summary, here we describe a novel approach using HMGB1specific DNA beads to effectively sequester HMGB1, and improve
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Figure 8. Administration of B2 beads ameliorates colitis-induced inflammation in IL-10 KO mice. Twelve weeks old female IL-10 KO mice
were orally administrated with 300 ml (50% slurry, gavage) of B2 or control beads three times a week for a total of six weeks. A) Treatment with B2
beads increased body weight in mice. *: p,0.05 vs. control beads group. N = 5–7 mice per group. N.T. = no treatment. B) Colon and serum
measurements of IL-10 KO mice treated with B2 or control beads. Colon measurements (weight, expression of IL-6 and IL-1b mRNA) and serum
HMGB1 levels in IL-10 KO mice treated with B2 or control beads. *: p,0.05 vs. control beads group. N = 5–7 mice per group. N.T. = no treatment. C)
Histological evaluation of B2 or control beads-treated IL-10 KO mice. Representative H&E staining of colon from wild type (C57BL/6) or IL-10 KO mice
and histological scores (see Methods) of colons are shown. *: p,0.05 vs. control beads group. N = 5–7 mice per group. Magnification: 640.
doi:10.1371/journal.pone.0103992.g008

disease pathogenesis in clinically relevant models of colitis. Given
the high affinity of HMGB1 to DNA, this DNA-based HMGB1
sequestration therapy in IBD may provide therapeutic advantages.
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